Pharmacogenetics and Mood Stabilization in Bipolar Disorder

American Journal of Medical Genetics - Seminars in Medical Genetics

Volumn 123 C, Issue 1, 2003, Pages 18-25

  Ruzickova, Martina ^a   Turecki, Gustavo ^b   Alda, Martin ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Bipolar disorder; Lithium; Pharmacogenetics; Treatment response

Indexed keywords

CARBAMAZEPINE; LITHIUM; VALPROIC ACID;

BIPOLAR DISORDER; DISEASE SEVERITY; FAMILY HISTORY; GENE EXPRESSION; GENE MAPPING; GENETIC POLYMORPHISM; HUMAN; MENTAL DISEASE; PATHOPHYSIOLOGY; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0242322783     PISSN: 15524868     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajmg.c.20010     Document Type: Review

References (67)

1. Abou-Saleh M, Coppen A. 1986. Who responds to prophylactic lithium? J Affect Disord 10:115-125.
2. Ahrens B, Muller-Oerlinghausen B, Schou M, Wolf T, Alda M, Grof E, Grof P, Lenz G, Simhandl C, Thau K, Vestergaard P, Wolf R, Moller HJ. 1995. Excess cardiovascular and suicide mortality of affective disorders may be reduced by lithium prophylaxis. J Affect Disord 33:67-75.
3. Alda M. 2001. Genetic factors and treatment of mood disorders. Bipolar Disord 3:318-324.
4. Alda M. 2002. Genetic factors and long-term prophylaxis in bipolar disorder. In: Lerer B, editor. Pharmacogenetics of psychotropic drugs. Cambridge: Cambridge University Press. p 320-332.
5. Alda M, Grof P, Grof E, Zvolsky P, Walsh M. 1994. Mode of inheritance in families of patients with lithium-responsive affective disorders. Acta Psychiatr Scand 90:304-310.
6. Alda M, Grof E, Cavazzoni P, Duffy A, Martin R, Ravindran L, Grof P. 1997. Autosomal recessive inheritance of affective disorders in families of responders to lithium prophylaxis? J Affect Disord 44:153-157.
7. Alda M, Grof P, Grof E. 1998. MN blood groups and bipolar disorder: evidence of genotypic association and Hardy-Weinberg disequilibrium. Biol Psychiatry 44:361-363.
8. Alda M, Cavazzoni P, Grof P. 1999. Treatment response to prophylactic lithium and family history of psychiatric disorders. Biol Psychiatry 45:1078.
9. Alda M, Turecki G, Grof P, Cavazzoni P, Duffy A, Grof E, Ahrens B, Berghofer A, Muller-Oerlinghausen B, Dvorakova M, Libigerova E, Vojtechovsky M, Zvolsky P, Nilsson A, Prochazka H, Licht RW, Rasmussen NA, Schou M, Vestergaard P, Holzinger A, Schumann C, Thau K, Rouleau GA. 2000. Association and linkage analyses of CRH and PENK genes in bipolar disorder responsive to lithium: a collaborative IGSLi study. Am J Med Genet 96:178-181.
10. Bowden CL, Brugger AM, Swann AC, Calabrese JR, Janicak PG, Petty F, Dilsaver SC, Davis JM, Rush AJ, Small JG. 1994. Efficacy of divalproex vs. lithium and placebo in the treatment of mania. JAMA 271:918-924.
11. Calabrese JR, Delucchi GA. 1990. Spectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar disorder. Am J Psychiatry 147:431-434.
12. Calabrese JR, Woyshville MJ. 1995. A medication algorithm for treatment of bipolar rapid cycling? J Clin Psychiatry 56(Suppl 3): 11-18.
13. Calabrese JR, Woyshville MJ, Kimmel SE, Rapport DJ. 1993. Predictors of valproate response in bipolar rapid cycling. J Clin Psychopharmacol 13:280-283.
14. Cavazzoni P, Alda M, Turecki G, Rouleau G, Grof E, Martin R, Duffy A, Grof P. 1996. Lithium-responsive affective disorders: no association with the tyrosine hydroxylase gene. Psychiatr Res 64:91-96.
15. Chen G, Zeng WZ, Yuan PX, Huang LD, Jiang YM, Zhao ZH, Manji HK. 1999. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J Neurochem 72:879-882.
16. Coppen A, Montgomery SA, Gupta RK, Bailey JE. 1976. A double-blind comparison of lithium carbonate and maprotiline in the prophylaxis of the affective disorders. Br J Psychiatry 128:79-85.
17. Coryell W, Akiskal H, Leon AC, Turvey C, Solomon D, Endicott J. 2000. Family history and symptom levels during treatment for bipolar I affective disorder. Biol Psychiatry 47:1034-1042.
18. Das Gupta R, Guest JF. 2002. Annual cost of bipolar disorder to UK society. Br J Psychiatry 180:227-233.
19. Del Zompo M, Ardau R, Palmas MA, Bocchetta A, Reina A, Piccardi MP. 1999. Lithium response: association study with two candidate genes. Mol Psychiatry 4:66-67.
20. Duffy A, Turecki G, Grof P, Cavazzoni P, Grof E, Joober R, Ahrens B, Berghofer A, Muller-Oerlinghausen B, Dvorakova M, Libigerova E, Vojtechovsky M, Zvolsky P, Nilsson A, Licht W, Rasmussen NA, Schou M, Vestergaard P, Holzinger A, Schumann C, Thau K, Rouleau GA, Alda M. 2000. Association and linkage studies of candidate genes involved in GABAergic neurotransmission in lithium responsive bipolar disorder. J Psychiatry Neurosci 25:353-358.
21. Dunner DL, Fleiss JL, Fieve RR. 1976. Lithium carbonate prophylaxis failure. Br J Psychiatry 129:40-44.
22. Engstrom C, Astrom M, Nordqvist-Karlsson B, Adolfsson R, Nylander PO. 1997. Relationship between prophylactic effect of lithium therapy and family history of affective disorders. Biol Psychiatry 42:425-433.
23. Ftouhi-Paquin N, Alda M, Grof P, Chretien N, Rouleau G, Turecki G. 2001. Identification of three polymorphisms in the translated region of PLC-1 and their investigation in lithium responsive bipolar disorder. Am J Med Genet 105:301-305.
24. Garnham J, Munro A, Teehan A, Duffy A, MacDougall M, Passmore M, Slaney C, Alda M. 2002. Naturalistic study of outcome of mood stabilizing treatment in bipolar disorder. Int J Neuropsychopharmacol 5(Suppl 1):55.
25. Ghaemi SN, Goodwin FK. 2001. Long-term naturalistic treatment of depressive symptoms in bipolar illness with divalproex vs. lithium in the setting of minimal antidepressant use. J Affect Disord 65:281-287.
26. Greil W, Kleindienst N. 1999a. Lithium versus carbamazepine in the maintenance treatment of bipolar II disorder and bipolar disorder not otherwise specified. Int Clin Psychopharmacol 14:283-285.
27. Greil W, Kleindienst N. 1999b. The comparative prophylactic efficacy of lithium and carbamazepine in patients with bipolar I disorder. Int Clin Psychopharmacol 14:277-281.
28. Greil W, Kleindienst N, Erazo N, Muller-Oerlinghausen B. 1998. Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. J Clin Psychopharmacol 18:455-460.
29. Grof P. 1983. Response to long-term lithium treatment: research studies and clinical implications. In: Davis JM, Maas JW, editors. The affective disorders. Washington, DC: American Psychiatric Press. p 357-366.
30. Grof P, Alda M. 2000. Discrepancies in the efficacy of lithium. Arch Gen Psychiatry 57:191.
31. Grof P, Alda M, Grof E, Fox D, Cameron P. 1993. The challenge of predicting response to stabilising lithium treatment. The importance of patient selection. Br J Psychiatry 163(Suppl 21):16-19.
32. Grof P, Alda M, Grof E, Zvolsky P, Walsh M. 1994. Lithium response and genetics of affective disorders. J Affect Disord 32:85-95.
33. Grof P, Duffy A, Cavazzoni P, Grof E, Garnham J, MacDougall M, O'Donovan C, Alda M. 2002. Is response to prophylactic lithium a familial trait? J Clin Psychiatry 63:942-947.
34. Hua LV, Green M, Warsh JJ, Li PP. 2000. Lithium regulation of aldolase A expression in the rat frontal cortex: identification by differential display. Biol Psychiatry 48:58-64.
35. Hua LV, Green M, Warsh JJ, Li PP. 2001a. Molecular cloning of a novel isoform of diphosphoinositol polyphosphate phosphohydrolase: a potential target of lithium therapy. Neuropsychopharmacology 24:640-651.
36. Hua LV, Green M, Wong A, Warsh JJ, Li PP. 2001b. Tetraspan protein CD151: a common target of mood stabilizing drugs? Neuropsychopharmacology 25:729-736.
37. Lerer B, Moore N, Meyendorff E, Cho SR, Gershon S. 1987. Carbamazepine versus lithium in mania: a double-blind study. J Clin Psychiatry 48:89-93.
38. Lovlie R, Berle JO, Stordal E, Steen VM. 2001. The phospholipase C-g1 gene (PLCG1) and lithium-responsive bipolar disorder: reexamination of an intronic dinucleotide repeat polymorphism. Psychiatr Genet 11:41-44.
39. Maj M, Del Vecchio M, Starace F, Pirozzi R, Kemali D. 1984. Prediction of affective psychoses response to lithium prophylaxis: the role of socio-demographic, clinical, psychological and biological variables. Acta Psychiatr Scand 69:37-44.
40. Mendlewicz J, Fieve RR, Stallone F. 1973. Relationship between the effectiveness of lithium therapy and family history. Am J Psychiatry 130:1011-1013.
41. Misra PC, Burns BH. 1976. "Lithium nonresponders" in a lithium clinic. Acta Psychiatr Scand 55:32-38.
42. Mundo E, Walker M, Cate T, Macciardi F, Kennedy JL. 2001. The role of serotonin transporter protein gene in antidepressant-induced mania in bipolar disorder. Arch Gen Psychiatry 58:539-544.
43. Osby U, Brandt L, Correia N, Ekbom A, Sparen P. 2001. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 58:844-850.
44. Passmore M, Garnham J, Duffy A, MacDougall M, Munro A, Slaney C, Teehan A, Alda M. 2003. Phenotypic spectra of bipolar disorder in responders to lithium versus lamotrigine. Bipolar Disord, 5:110-114.
45. Post RM, Uhde TW, Roy-Byrne PP, Joffe RT. 1987. Correlates of antimanic response to carbamazepine. Psychiatr Res 21:71-83.
46. Prien RF, Caffey EM, Klett CJ. 1974. Factors associated with treatment success in lithium carbonate prophylaxis: report of the Veterans Administration and National Institute of Mental Health Collaborative Study Group. Arch Gen Psychiatry 31:189-192.
47. Serretti A, Lilli R, Lorenzi C, Franchini L, Smeraldi E. 1998. Dopamine receptor D3 gene and response to lithium prophylaxis in mood disorders. Int J Neuropsychopharmacol 1:125-129.
48. Serretti A, Lilli R, Lorenzi C, Franchini L, Di Bella D, Catalano M, Smeraldi E. 1999a. Dopamine receptor D2 and D4 genes, GABA(A) alpha-1 subunit genes and response to lithium prophylaxis in mood disorders. Psychiatr Res 87:7-19.
49. Serretti A, Lilli R, Lorenzi C, Gasperini M, Smeraldi E. 1999b. Tryptophan hydroxylase gene and response to lithium prophylaxis in mood disorders. J Psychiatr Res 33:371-377.
50. Serretti A, Lorenzi C, Lilli R, Smeraldi E. 2000. Serotonin receptor 2A, 2C, 1A genes and response to lithium prophylaxis in mood disorders. J Psychiatr Res 34:89-98.
51. Serretti A, Lilli R, Mandelli L, Lorenzi C, Smeraldi E. 2001. Serotonin transporter gene associated with lithium prophylaxis in mood disorders. Pharmacogenomics J 1:71-77.
52. Serretti A, Lorenzi C, Lilli R, Mandelli L, Pirovano A, Smeraldi E. 2002. Pharmacogenetics of lithium prophylaxis in mood disorders: analysis of COMT, MAO-A, and Gbeta3 variants. Am J Med Genet 114:370-379.
53. Smeraldi E, Petroccione A, Gasperini M, Macciardi F, Orsini A, Kidd KK. 1984. Outcomes on lithium treatment as a tool for genetic studies in affective disorders. J Affect Disord 6:139-151.
54. Steen VM, Lovlie R, Osher Y, Belmaker RH, Berle JO, Gulbrandsen AK. 1998. The polymorphic inositol polyphosphate 1-phosphatase gene as a candidate for pharmacogenetic prediction of lithium-responsive manic-depressive illness. Pharmacogenetics 8:259-268.
55. Strober M, Morrell W, Burroughs J, Lampert C, Danforth H, Freeman R. 1988. A family study of bipolar I disorder in adolescence: early onset of symptoms linked to increased familial loading and lithium resistance. J Affect Disord 15:255-268.
56. Svestka J. 1979. Therapy and prophylaxis of manic-depressive psychosis with lithium carbonate, with respect to possibility of prediction of the therapeutic result. Acta Facult Med Univ Brunensis 65:25-102.
57. Swann AC, Bowden CL, Calabrese JR, Dilsaver SC, Morris DD. 2002. Pattern of response to divalproex, lithium, or placebo in four naturalistic subtypes of mania. Neuropsychopharmacology 26:530-536.
58. The World Health Report. 2001. http://www. who.int/whr2001/2001/main/en/contents. htm
59. Turecki G, Alda M, Grof P, Grof E, Martin R, Cavazzoni PA, Duffy A, Maciel P, Rouleau GA. 1996. No association between chromosome-18 markers and lithium responsive affective disorders. Psychiatr Res 63:17-23.
60. Turecki G, Grof P, Cavazzoni P, Duffy A, Grof E, Ahrens B, Berghofer A, Muller-Oerlinghausen B, Dvorakova M, Libigerova E, Vojtechovsky M, Zvolsky P, Joober R, Nilsson A, Prochazka H, Licht RW, Rasmussen NA, Schou M, Vestergaard P, Holzinger A, Schumann C, Thau K, Rouleau GA, Alda M. 1998. Evidence for a role of phospholipase C-gamma1 in the pathogenesis of bipolar disorder. Mol Psychiatry 3:534-538.
61. Turecki G, Grof P, Cavazzoni P, Duffy A, Grof E, Ahrens B, Berghofer A, Muller-Oerlinghausen B, Dvorakova M, Libigerova E, Vojtechovsky M, Zvolsky P, Joober R, Nilsson A, Prochazka H, Licht RW, Rasmussen NA, Schou M, Vestergaard P, Holzinger A, Schumann C, Thau K, Rouleau GA, Alda M. 1999. MAOA: association and linkage studies with lithium responsive bipolar disorder. Psychiatr Genet 9:13-16.
62. Turecki G, Alda M, Grof P, Joober R, Lafreniere R, Cavazzoni P, Duffy A, Grof E, Ahrens B, Berghofer A, Muller-Oerlinghausen B, Dvorakova M, Libigerova E, Vojtechovsky M, Zvolsky P, Nilsson A, Prochazka H, Licht RW, Rasmussen NA, Schou M, Vestergaard P, Holzinger A, Schumann C, Thau K, Rouleau GA. 2000. Polyglutamine coding genes in bipolar disorder. Lack of association with selected candidate loci. J Affect Disord 53:63-68.
63. Turecki G, Grof P, Grof E, D'Souza V, Lebuis L, Marineau C, Cavazzoni P, Duffy A, Betard C, Zvolsky P, Robertson C, Brewer C, Hudson TJ, Rouleau GA, Alda M. 2001. Mapping susceptibility genes for bipolar disorder: a pharmacogenetic approach based on excellent response to lithium. Mol Psychiatry 6:570-578.
64. Wang JF, Bown C, Young LT. 1999. Differential display PCR reveals novel targets for the mood stabilizing drug valproate including the molecular chaperone GRP78. Mol Pharmacol 55:521-527.
65. Wang JF, Sun X, Chen B, Young LT. 2002. Lamotrigine increases gene expression of GABA-A receptor beta3 subunit in primary cultured rat hippocampus cells. Neuropsychopharmacology 26:415-421.
66. Wyatt RJ, Henter I. 1995. An economic evaluation of manic-depressive illness 1991. Soc Psychiatry Psychiatr Epidemiol 30:213-219.
67. Zvolsky P, Vinarova E, Dostal T, Soucek K. 1974. Family history of manic-depressive and endogenous depressive patients and clinical effect of treatment with lithium. Act Nerv Super (Praha) 16:194-195.